Used primarily as a selective antagonist for metabotropic glutamate receptor 7 (mGluR7), MMPIP is employed in neuroscience research to study synaptic transmission and glutamatergic signaling. It helps investigate the role of mGluR7 in anxiety, depression, and cognitive disorders. Due to its ability to modulate neurotransmitter release, it is also used in studies exploring pain pathways and neurodegenerative conditions. Its application is limited to in vitro and preclinical models, supporting the development of targeted CNS therapeutics.